Anatomical Therapeutic Chemical • L01FF02 • pembrolizumab

L Antineoplastic and immunomodulating agents

L01 Antineoplastic agents

L01A Alkylating agents

L01B Antimetabolites

L01C Plant alkaloids and other natural products

L01D Cytotoxic antibiotics and related substances

L01E Protein kinase inhibitors

L01F Monoclonal antibodies and antibody drug conjugates

L01FA Cd20 (clusters of differentiation 20) inhibitors

L01FB Cd22 (clusters of differentiation 22) inhibitors

L01FC Cd38 (clusters of differentiation 38) inhibitors

L01FD Her2 (human epidermal growth factor receptor 2) inhibitors

L01FE Egfr (epidermal growth factor receptor) inhibitors

L01FF Pd-1/pdl-1 (programmed cell death protein 1/death ligand 1) inhibitors

L01FF01 nivolumab Indicated for: cancer

L01FF02 pembrolizumab Indicated for: cancer

L01FF03 durvalumab Indicated for: cancer

L01FF05 atezolizumab Indicated for: cancer

L01FF06 cemiplimab Indicated for: cancer

L01FF09 tislelizumab Indicated for: cancer

L01FF10 retifanlimab Indicated for: cancer

L01FF12 serplulimab Indicated for: cancer

L01FF13 toripalimab Indicated for: cancer

L01FG Vegf/vegfr (vascular endothelial growth factor) inhibitors

L01FX Other monoclonal antibodies and antibody drug conjugates

L01FY Combinations of monoclonal antibodies and antibody drug conjugates

L01X Other antineoplastic agents

L02 Endocrine therapy

L03 Immunostimulants

L04 Immunosuppressants